All In Biotech

Drug Trial Radar · NCT04659304

Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

A Multi-Center , Sequential Dose Escalation Study, Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

Last checked: Nov 19, 2026Latest source record: Aug 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18

Planned (sponsor's estimate)

Start

Dec 2021

Primary completion

Sep 2022

Study completion Dec 2022

Sponsor

Lead sponsor
Enlivex Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Dec 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b, multi-center, open label, sequential dose escalation trial assessing 3 dose cohorts using a 3+3 design to evaluate safety and tolerability of Allocetra-OTS in adult patients with moderate COVID-19. The sample size for this trial is anticipated to range from 9 to 18 patients.

Conditions

  • Covid19

Interventions

  • Allocetra-OTSDrug

    Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Adverse EventsTime frame: 28 days
  2. Maximum Tolerated Dose (MTD)Time frame: 28 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.